← All funding rounds

BioVersys raises €25.2M Series C round

8 June 2022· Basel, Switzerland· health, biotech, drug_discovery, antimicrobial_resistance, b2b

To initiate first Phase II clinical trials of BV100 and BVL-GSK098 and the preclinical development of BV200.

Investors

LeadAMR Action Fund

Also participating

CR Ventures

About BioVersys

Stage

Series C

Headquarters

Basel, Switzerland

Founded

2008

Team Size

21–50

Sectors

healthbiotechdrug_discoveryantimicrobial_resistanceb2b

http://www.bioversys.com/

Source: https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGA1FiSQkxuaMHnXIePbt5fLY929bClc-JW5gGRBqQhk8RgrpwSc77H6m2eE3bim24EVFP9OkKOuuCL_8jkTTf0-ApRrzEQ0YgY9h-HfrZCty2EEjklr4bS07fscz9wjjsN2kXj38Wqitle57HXDZbOpvn2tDm5VTXOUiZAP7rZuwV78A4PveLS6y9u3CN12FbhdZIg==, https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH__rkO4_ynYaIemfYtz9E6NnZDD_to0XJxbB7tGZ3T0niQ-47PPqt7Ca2cZ9MCGmIjuoo-_vKlAUFGhYvfswf65DgZDf0cSINUveCuCaJXPaKimM_V1EnsGcFBetoHVjGe1pyUGMMVwboqoHaT4ThwRglIm54FqeRb7m7WI2jdcZMuKTLEeHK-fQ-1JyyxaAmXQYjxm7wK8SZLi5pB6-5BRZmx0baeBtngLxnAkw==, https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF4YSfHxCTSYO1iH-40DvbclqOZIQIGxBU-f6VSm4rw52lV1no3SxDUqa3_hXKkinwRyv44GhoVwqPohe5BN9djjNqpMX4H81bYAF0yI_SqRHbZBX63GTqb9zHHS84ZFoCrgtQiQ_sFxa7Once1Eghf7h1m9lcT7y2Uj5k4WYJQ3jLaLM22zkNNVYXhbcai4VRZ